Theramex

Theramex is a specialty pharmaceutical company dedicated exclusively to women's health, covering the full spectrum of a woman's life from contraception and fertility through to menopause and osteoporosis. Founded in 2018 following its acquisition from Teva Pharmaceutical Industries by CVC Capital Partners, the company operates as an independent, women's health-focused business with a clear commercial and scientific mission.

Headquartered in London, Theramex has built a European-centred footprint while maintaining a global commercial presence across more than 50 countries. The company markets an established portfolio of women's health medicines, including products in hormone replacement therapy, contraception, and bone health, working with healthcare professionals to ensure access to treatments that address conditions affecting women at distinct life stages.

What distinguishes Theramex in the specialty pharma landscape is its singular focus. Rather than managing women's health as one therapeutic division among many, the company has structured its entire organisation, medical affairs function, and commercial infrastructure around this single area. This concentrated model allows the business to engage deeply with gynaecologists, endocrinologists, general practitioners, and patient advocacy groups with a coherence that larger, more diversified organisations often cannot replicate.

Theramex continues to expand its portfolio through licensing, partnerships, and selective acquisitions, broadening the range of conditions it addresses within women's lifecycle health. Its approach combines an established base of marketed products with an interest in emerging therapies relevant to its therapeutic focus.

Further information is available at theramex.com.